Named on 3 rounds in the feed, most often at Series D+ and in Biotech.
Rounds from 2026-10-19 to 2026-11-11
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
VectorY Therapeutics A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases | Series A Verified against 1 of 10 sources | $82.9M | 2026-11-11 | [ PART ] |
Nouscom Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations. | Series D Verified against 4 of 10 sources | $133.8M | 2026-10-19 | [ PART ] |
Nouscom A clinical-stage, cancer interception focused biotech developing next-generation immunotherapies | Series D Verified against 4 of 41 sources | $134.7M | 2026-10-19 | [ PART ] |